Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Quarterly call transcripts
View:
Post by mdjbrown on Jun 19, 2024 12:11pm

Quarterly call transcripts

If you have time to go back and read the quarterly call transcripts back to 2020, there is a lot of good info directly from the execs.
 
Q2, 2023
‘If and when our pharmaceutical partner is successful in their generic application to produce a generic Epidiolex and distribute it’……………………
 
Q3, 2023
“There are many other great commercial projects happening at MediPharm, including preparing for a CBD natural health product channel in Canada, preparing for future generic Epidiolex in the U.S. and growing our clinical study business.”
 
https://www.alphaspread.com/security/tsx/labs/earnings-calls/q4-2023
Comment by QContinuum1 on Jun 19, 2024 2:31pm
They can state they are preparing for Epidiolex launch all they'd like, but facts are facts, the ANDA associated with that is going nowhere until the patent litigation is settled (positively).  If negative, it goes nowhere, if positive it may well take a fair bit more time to even get FDA approval, let alone start with production. It would be a (very) nice thing to have obviously, but if ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities